Ketamine FDA Approval, Off-Label Use, and Compounded Medication

Important: Compounded ketamine is not FDA-approved. FDA has not evaluated its safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric conditions. Compounded ketamine nasal spray is different from FDA-approved Spravato (esketamine), and research on other formulations or treatment settings does not establish its benefits.

FDA-approved, off-label, and compounded describe different things. Knowing the difference can help you ask clearer questions when a website or clinician discusses ketamine treatment.

FDA approval applies to a specific product

Approval concerns a particular drug product and its labeled uses. Injectable ketamine is approved for anesthesia. Spravato is an approved esketamine nasal spray with specific depression indications and monitoring requirements. Approval of either product does not transfer to another formulation or combination of ingredients.

Off-label use does not create a new approval

Off-label prescribing refers to using an approved medication in a way that differs from its approved labeling, such as for a different condition. An example is use of an approved ketamine injection product for depression. The phrase describes how a medication is prescribed; it does not establish FDA approval of that psychiatric use.

Compounding is a separate issue

Compounding involves preparing or altering medication for an individual medical need. A compounded ketamine nasal spray is itself an unapproved drug product. Calling it off-label should not obscure that distinction. FDA explains this in its information about compounded-drug risks.

A prescription is also not a blanket assurance that every ingredient, formulation, or distribution arrangement satisfies applicable requirements. The prescribing clinician and pharmacy have responsibilities that depend on the actual circumstances. This article is patient education, not a legal determination about any specific prescription.

What to verify before deciding

• Ask for the medication’s exact name, ingredients, route, and approval status.
• Ask why an approved treatment would not meet your medical needs.
• Find out which pharmacy would prepare and dispense the prescription.
• Request clear instructions and a plan for adverse effects and follow-up.

A pharmacy’s license, an ingredient’s history of medical use, or a clinician’s prescription should not be presented as FDA approval of a compounded product. Research findings should also be matched to the exact intervention studied.

The Spravato label is a useful reference when comparing that approved product with other options, but its treatment protocol should not be copied onto a compounded prescription.

Safety and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, nausea, increased blood pressure or heart rate, and slowed breathing. Abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems are also concerns. This is not a complete list of risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Telehealth support does not provide the same monitoring as an onsite care team. Review these FDA ketamine risk alerts and discuss your health history, other medications, monitoring needs, and emergency plan with your clinician.

Discuss your options

Bliss Mist Rx LLC provides telehealth services; we do not manufacture or compound medication. If a clinician prescribes treatment, an independent, appropriately licensed compounding pharmacy dispenses it. A consultation does not guarantee a prescription or a particular outcome. Book a Free Virtual Appointment or Follow-Up to discuss questions about your care.

This article is general education and does not replace individualized medical advice.